Price
CHART BY
Frequently asked questions
What is VERU INC. NEW's market capitalization?
The market capitalization of VERU INC. NEW is $41.09M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for VERU INC. NEW?
VERU INC. NEW's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.611. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for VERU INC. NEW's stock?
Currently, 1 analysts cover VERU INC. NEW's stock, with a consensus target price of $25.00. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for VERU INC. NEW?
VERU INC. NEW's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$27.70M. EBITDA measures the company's overall financial performance.
What is the free cash flow of VERU INC. NEW?
VERU INC. NEW has a free cash flow of -$26.04M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does VERU INC. NEW have, and what sector and industry does it belong to?
VERU INC. NEW employs approximately 20 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of VERU INC. NEW's shares?
The free float of VERU INC. NEW is 14.99M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $41.09M
- EPS (TTM)
- -$0.611
- Free Float
- 14.99M
- EBITDA (TTM)
- -$27.70M
- Free Cashflow (TTM)
- -$26.04M
Pricing
- 52W span
- $2.05$7.32
Analyst Ratings
The price target is $25.00 and the stock is covered by 1 analysts.
Buy
1
Hold
0
Sell
0
Information
Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines and treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. The company was founded by William R. Gargiulo, Jr. and O. B. Parrish in 1971 and is headquartered in Miami, FL.
- Employees
- 20
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- VERU
Fundamentals & EOD data from FactSet